2015
Thrombotic Microangiopathy, Cancer, and Cancer Drugs
Izzedine H, Perazella MA. Thrombotic Microangiopathy, Cancer, and Cancer Drugs. American Journal Of Kidney Diseases 2015, 66: 857-868. PMID: 25943718, DOI: 10.1053/j.ajkd.2015.02.340.Peer-Reviewed Original ResearchConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsLong-term kidney injuryManagement of TMACell damageGrowth factor agentsAnti-VEGF agentsEndothelial cell damageType I agentsChemotherapy regimensDrug interruptionFactor agentsKidney injuryImmunologic basisClinical courseFunctional recoveryImmunosuppressive agentsKidney functionCertain malignanciesI agentsPhysician guidanceAnticancer therapySuccessful diagnosis
2004
Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
2001
Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs
Perazella M, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. The American Journal Of Medicine 2001, 111: 64-67. PMID: 11448662, DOI: 10.1016/s0002-9343(01)00757-4.Peer-Reviewed Original ResearchCOX-2 Inhibitors and the Kidney
Perazella M. COX-2 Inhibitors and the Kidney. Hospital Practice 2001, 36: 43-56. PMID: 11263799, DOI: 10.3810/hp.2001.03.230.Peer-Reviewed Original Research
2000
Are selective COX-2 inhibitors nephrotoxic?
Perazella M, Eras J. Are selective COX-2 inhibitors nephrotoxic? American Journal Of Kidney Diseases 2000, 35: 937-940. PMID: 10793030, DOI: 10.1016/s0272-6386(00)70266-6.Peer-Reviewed Original ResearchConceptsHigh-risk patientsRenal insufficiencySelective cyclooxygenase-2 enzyme inhibitorsSuch high-risk patientsNonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsChronic renal impairmentChronic renal insufficiencyAcute renal failureAcute renal insufficiencyAdverse gastrointestinal effectsCyclooxygenase-2 enzyme inhibitorsAnti-inflammatory drugsCourse of therapyCOX-2 inhibitorsPain syndromeRenal impairmentRenal failureGastrointestinal effectsNephrotoxic potentialInflammatory diseasesEnzyme inhibitorsPatientsInsufficiencyInhibitorsTrimethoprim-Induced Hyperkalaemia
Perazella M. Trimethoprim-Induced Hyperkalaemia. Drug Safety 2000, 22: 227-236. PMID: 10738846, DOI: 10.2165/00002018-200022030-00006.Peer-Reviewed Original ResearchConceptsRenal potassium excretionPotassium excretionHigh urinary flow ratesPotassium homeostasisManagement of hyperkalaemiaGlomerular filtration ratePotassium-sparing diuretic amilorideUrinary flow rateRecognition of patientsDistal nephron cellsTrimethoprim therapyRenal impairmentCommon complicationLoop diureticsEpithelial sodium channelIntravenous fluidsVolume repletionAdverse reactionsFiltration rateRisk factorsStandard dosageAntikaliuretic effectHyperkalaemiaIsotonic fluidsDistal nephron
1999
Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension
Cruz D, Mahnensmith R, Brickel H, Perazella M. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension. American Journal Of Kidney Diseases 1999, 33: 920-926. PMID: 10213650, DOI: 10.1016/s0272-6386(99)70427-0.Peer-Reviewed Original ResearchConceptsSymptomatic intradialytic hypotensionPost-HD blood pressuresIntradialytic blood pressureIntradialytic hypotensionBlood pressureEffective therapyLaboratory valuesCombination therapy phaseConsecutive HD treatmentsProspective crossover studyBlood pressure measurementsKt/VVolume of salineControl phaseAlpha1 agonistHypotensive symptomsMorbid complicationCrossover studyUseful therapyProspective studyNursing interventionsHD treatmentMidodrineTreatment phaseTherapy phaseExtreme Hyperphosphatemia and Acute Renal Failure after a Phosphorus-Containing Bowel Regimen
Orias M, Mahnensmith R, Perazella M. Extreme Hyperphosphatemia and Acute Renal Failure after a Phosphorus-Containing Bowel Regimen. American Journal Of Nephrology 1999, 19: 60-63. PMID: 10085452, DOI: 10.1159/000013427.Peer-Reviewed Case Reports and Technical NotesConceptsAcute renal failureRenal failureOliguric acute renal failureBowel-cleansing preparationsBowel-cleansing regimenBowel regimenExtreme hyperphosphatemiaHypocalcemic tetanyGastrointestinal proceduresRenal excretionGastrointestinal transitPatientsIntoxicationRegimenFailureHyperphosphatemiaRegimensExcretionDiseaseTetanyRinger's lactate: An inexpensive and effective dialysate for continuous renal replacement therapy
Perazella M, Cruz D. Ringer's lactate: An inexpensive and effective dialysate for continuous renal replacement therapy. American Journal Of Kidney Diseases 1999, 33: 614-615. PMID: 10070931, DOI: 10.1016/s0272-6386(99)70206-4.Peer-Reviewed Original Research
1998
Acute Renal Failure and Intravenous Immune Globulin
Perazella M, Cayco A. Acute Renal Failure and Intravenous Immune Globulin. American Journal Of Therapeutics 1998, 5: 399-404. PMID: 10099084, DOI: 10.1097/00045391-199811000-00008.Peer-Reviewed Original ResearchConceptsAcute renal failureRenal failureRenal insufficiencyIntravenous immune globulin therapyImmune globulin therapyChronic renal insufficiencyIntravenous immune globulinAcute renal insufficiencyRenal replacement therapyVariety of complicationsGlobulin therapyIVIG infusionIVIG therapyMaintenance dialysisRenal impairmentImmune globulinIVIG preparationsReplacement therapyDrug trialsNumber of casesClinical disordersOlder agePrecise causeTherapyAdverse effectsReduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol
Cayco A, Abu-Alfa A, Mahnensmith R, Perazella M. Reduction in arteriovenous graft impairment: Results of a vascular access surveillance protocol. American Journal Of Kidney Diseases 1998, 32: 302-308. PMID: 9708617, DOI: 10.1053/ajkd.1998.v32.pm9708617.Peer-Reviewed Original ResearchConceptsDynamic venous pressureHistorical control groupVenous pressureArteriovenous graftsSurveillance protocolStudy groupBlood flow rateThrombosis rateControl groupSimilar historical control groupHemodialysis vascular accessSynthetic arteriovenous graftsLower thrombosis rateML/minGraft impairmentVenous stenosisHD sessionVascular accessVascular stenosisPatientsScreening testStenosisStudy periodFrustrating problemConsecutive readings
1997
Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients?
Cruz D, Mahnensmith R, Perazella M. Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients? American Journal Of Kidney Diseases 1997, 30: 772-779. PMID: 9398120, DOI: 10.1016/s0272-6386(97)90081-0.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdrenergic alpha-AgonistsAgedAged, 80 and overBlood PressureDiastoleDizzinessFatigueFemaleFollow-Up StudiesHumansHypotensionKidney Failure, ChronicLongitudinal StudiesMaleMiddle AgedMidodrineMuscle CrampMuscle WeaknessParesthesiaProspective StudiesPulseRenal DialysisRisk FactorsSafetyScalpSystoleConceptsDiastolic blood pressureSystolic blood pressureBlood pressureMidodrine therapyArterial pressureHemodialysis patientsIntradialytic hypotensionPulse rateEnd-stage renal disease patientsIntradialytic systolic blood pressureEfficacy of midodrineSymptomatic hemodialysis patientsNeurogenic orthostatic hypotensionMean arterial pressureRenal disease patientsAdequate patient numbersBlood pressure measurementsAlpha-adrenergic agonist activityConsecutive dialysis sessionsAutonomic dysfunctionDialysis hypotensionOral agentsOrthostatic hypotensionSymptomatic hypotensionProspective trialHyperkalemia in the Elderly
Perazella M, Mahnensmith R. Hyperkalemia in the Elderly. Journal Of General Internal Medicine 1997, 12: 646-656. PMID: 9346463, PMCID: PMC1497179, DOI: 10.1046/j.1525-1497.1997.07128.x.Peer-Reviewed Original ResearchConceptsDevelopment of hyperkalemiaPotassium-altering medicationsAppropriate managementPrevention of hyperkalemiaHigh-risk medicationsManagement of hyperkalemiaCellular potassium uptakePlasma potassium concentrationPertinent review articlesCardiac complicationsElderly patientsPotassium handlingRenal functionSevere hyperkalemiaCertain medicationsElectrolyte disordersGeriatric patientsClinical manifestationsElderly subjectsMEDLINE searchHyperkalemiaMedicationsDisease processRenal disposalPotassium levelsDysuria in an Elderly Man with Cardiomyopathy
Perazella M, Mahnensmith R. Dysuria in an Elderly Man with Cardiomyopathy. Hospital Practice 1997, 32: 147-154. PMID: 9006590, DOI: 10.1080/21548331.1997.11443412.Peer-Reviewed Original Research
1996
Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole.
Alappan R, Perazella M, Buller G. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Annals Of Internal Medicine 1996, 124: 316-20. PMID: 8554227, DOI: 10.7326/0003-4819-124-3-199602010-00006.Peer-Reviewed Original ResearchConceptsSerum potassium concentrationSerum creatinine levelsMumol/LBlood urea nitrogen levelsPeak potassium concentrationTrimethoprim-sulfamethoxazole therapyCreatinine levelsUrea nitrogen levelsTrimethoprim-sulfamethoxazoleTreatment groupsPotassium concentrationControl groupCommunity-based teaching hospitalDevelopment of hyperkalemiaDays of therapyProspective chart reviewConcurrent renal insufficiencyRenal insufficiencyChart reviewSevere hyperkalemiaHospitalized patientsSerum sodiumTeaching hospitalAnion gapPatients
1995
Hypercalcemia, sarcoidosis, and normal chest radiographs
Sander S, Buller G, Perazella M. Hypercalcemia, sarcoidosis, and normal chest radiographs. The American Journal Of Medicine 1995, 99: 437-438. PMID: 7573103, DOI: 10.1016/s0002-9343(99)80196-x.Peer-Reviewed Original ResearchEnalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels
Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia M. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. American Journal Of Kidney Diseases 1995, 26: 495-500. PMID: 7645558, DOI: 10.1016/0272-6386(95)90496-4.Peer-Reviewed Original ResearchConceptsRed blood cell massBlood cell massErythropoietin levelsEnalapril therapyPosttransplant erythrocytosisHemoglobin concentrationMU/mLElevated red blood cell massMean reticulocyte countRed blood cell destructionRenal transplant patientsMean pretreatment valuePlasma volume contractionMean levelsMean hemoglobin concentrationBlood cell destructionRed blood cell productionMechanism of actionEnalapril treatmentTransplant patientsMean hematocritPretreatment valuesBlood cell productionReticulocyte countEnzyme inhibitors
1994
Nephrotic Syndrome Associated with Agnogenic Myeloid Metaplasia
Perazella M, Buller G. Nephrotic Syndrome Associated with Agnogenic Myeloid Metaplasia. American Journal Of Nephrology 1994, 14: 223-225. PMID: 7977486, DOI: 10.1159/000168720.Peer-Reviewed Original Research
1993
NSAID Nephrotoxicity Revisited: Acute Renal Failure Due to Parenteral Ketorolac
PERAZELLA M, BULLER G. NSAID Nephrotoxicity Revisited: Acute Renal Failure Due to Parenteral Ketorolac. Southern Medical Journal 1993, 86: 1421-1424. PMID: 8272928, DOI: 10.1097/00007611-199312000-00025.Peer-Reviewed Original ResearchConceptsNSAID nephrotoxicityAcute renal failureSevere postoperative painMajor surgical proceduresKetorolac therapyParenteral ketorolacRenal hypoperfusionNonsurgical patientsPostoperative painRenal insufficiencyElderly patientsNonnarcotic analgesicsOral NSAIDsRenal failureRenal functionSuch patientsUrine outputSurgical proceduresKetorolacPatientsMedical literatureNephrotoxicitySuch proceduresSame degreeHypoperfusionRenal Failure and Severe Hypokalemia Associated With Acute Myelomonocytic Leukemia
Perazella M, Eisen R, Frederick W, Brown E. Renal Failure and Severe Hypokalemia Associated With Acute Myelomonocytic Leukemia. American Journal Of Kidney Diseases 1993, 22: 462-467. PMID: 8372846, DOI: 10.1016/s0272-6386(12)70154-3.Peer-Reviewed Original ResearchConceptsAcute myelomonocytic leukemiaRenal failureMyelomonocytic leukemiaRenal parenchymal infiltrationRenal tubular injuryHypokalemia AssociatedInappropriate kaliuresisMicrovascular insufficiencyRenal insufficiencySevere hypokalemiaTubular injuryParenchymal infiltrationSetting of leukemiaBlast cellsLeukemiaMetabolic perturbationsHypokalemiaVariety of mechanismsInsufficiencyFailureLeukostasisKaliuresisEtiologyInjury